1-Benzyl-3-hydrazinylpyrrolidine | 887594-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Benzyl-3-hydrazinylpyrrolidine
• 英文别名: (1-benzylpyrrolidin-3-yl)hydrazine
• CAS: 887594-74-3
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.276
• InChiKey: RRMYEVSAFFPAEV-UHFFFAOYSA-N

物化性质

• 沸点：
  322.1±31.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-Benzyl-3-hydrazinylpyrrolidine 在 吗啉 、 盐酸 、 sulfur 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 丙酮 为溶剂， 反应 3.0h， 生成 2-Amino-7-(1-benzylpyrrolidin-3-yl)-4,5-dihydrothieno[2,3-e]indazole-3-carbonitrile
  参考文献：
  名称：

  Novel dihydrothieno[2,3-e]indazole derivatives as IκB kinase inhibitors

  摘要：

  Synthesis, and structure-activity relationship (SAR) studies of the novel IKK-beta inhibitors 2 and 3 characterized by a dihydrothieno[2,3-e]indazole core are presented. Compound 2t was efficacious in a mouse model of LPS-stimulated TNF-alpha production. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.069

文献信息

• [EN] HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS AMINO-PYRIDINE SUBSTITUÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：EPIZYME INC

  公开号：WO2016044666A1

  公开（公告）日：2016-03-24

  The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开涉及杂环取代的氨基吡啶化合物。本公开还涉及含有这些化合物的药物组合物，以及通过将这些化合物和药物组合物用于需要的受试者来治疗癌症的方法。本公开还涉及将这些化合物用于研究或其他非治疗目的的用途。
• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：EP3792256A1

  公开（公告）日：2021-03-17

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了式 I 的化合物或其药学上可接受的盐，它们能调节磷酸肌醇 3-激酶-γ（PI3Kγ）的活性，可用于治疗与 PI3Kγ 活性有关的疾病，例如包括自身免疫性疾病、癌症、心血管疾病和神经退行性疾病。
• PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：EP3400221B1

  公开（公告）日：2020-08-26
• HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Epizyme, Inc.

  公开号：US20170291890A1

  公开（公告）日：2017-10-12

  The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.